All articles tagged with #osteoblasts
Researchers link the GPR133 (ADGRD1) receptor to bone density, showing that activating it with the chemical AP503 strengthens bones in mice and works with exercise, suggesting a potential path to reversing osteoporosis—though human trials are still needed and findings are currently in animal models.
Leipzig University researchers have identified GPR133 (ADGRD1) as a mechanosensitive receptor that promotes bone formation and limits bone resorption, strengthening bones. The receptor can be activated by AP503, which improved bone strength in both healthy and osteoporosis-model mice, offering a potential new drug target for osteoporosis and possibly age-related bone and muscle decline. Findings are preclinical, and further studies are needed before human treatments.
Johns Hopkins researchers in Bone Research found that parathyroid hormone, already used for osteoporosis, may prevent and reverse growth of pain-sensing nerves into damaged spinal regions by triggering Slit3, a protein that repels nerve fibers; in animal models, 1–2 months of PTH treatment produced denser vertebral endplates and reduced aberrant innervation, suggesting a potential disease-modifying approach for spinal degeneration, though human trials and safety considerations remain.
New research shows that activating the GPR133 receptor with the compound AP503 boosts osteoblast-driven bone formation, dramatically increasing bone density and strength in osteoporotic mice and even stronger when combined with exercise; the approach could shift osteoporosis treatment from slowing bone loss to rebuilding bone, but it remains early-stage animal research with no human trials yet.
A 2025 study from Leipzig and Shandong identifies the GPR133 (ADGRD1) receptor as crucial for bone density. Activating it with the chemical AP503 increases osteoblast activity and bone strength in mice, suggesting a potential therapy for osteoporosis that could work with exercise. While promising, these results are in animal models and require human testing; related 2024 work on a blood‑based regenerative implant and bone‑density hormones may inform future treatments.
Scientists at the University of Hong Kong identify Piezo1 as an exercise-sensing protein in bone marrow stem cells that shifts fate toward bone-forming osteoblasts and away from fat cells; mice lacking Piezo1 show weaker bones and reduced exercise benefits, while activating its pathway could mimic exercise to combat osteoporosis—though findings are preclinical and demand cautious development for human therapies.